Testen Sie Ihr Fachwissen

FRAGEN

• Wie lautet Ihre Diagnose?

Publikationsverlauf

Artikel online veröffentlicht:
14. Juli 2020

• Literatur

• 1 Kempf W, Kazakov DV, Kerl KP. Cutaneous lymphomas: an update. Part 1: T cell and natural killer/t-cell lymphomas and related conditions. Am J Dermatopathol 2014; 36: 105-123
• 2 Dippel E, Assaf C, Becker JC. et al. S2k-Leitlinie – Kutane Lymphome Update 2016 – Teil 1: Klassifikation und Diagnostik (ICD10 C82-C86). J Dtsch Dermatol Ges 2017; 15: 1266-1273
• 3 Dippel E, Assaf C, Becker JC. et al. S2k-Leitlinie – Kutane Lymphome Update 2016 – Teil 2: Therapie und Nachsorge (ICD10 C82-C86). J Dtsch Dermatol Ges 2018; 16: 112-123
• 4 Fierro MT, Quaglino P, Savoia P. et al. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 1998; 31: 583-588
• 5 Younes A, Bartlett NL, Leonard JP. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821
• 6 Mahévas T, Ram-Wolff C, Battistella M. et al. Dramatic response to brentuximab vedotin in a refractory non-transformed CD30^– mycosis fungoides allowing allogeneic stem cells transplantation and long-term complete remission. Br J Dermatol 2019; 180: 1517-1520
• 7 Pham AK, Carter JB, Ratcliffe NR. et al. Tumor-stage mycosis fungoides in palmoplantar localization with large-cell transformation and partial CD30 expression shows complete response to brentuximab vedotin. J Cutan Pathol 2018; 45: 458-462
• 8 Gatzka M. Targeted Tumor Therapy Remixed – An Update on the Use of Small-Molecule Drugs in Combination Therapies. Cancers 2018; 10: pii: E155
• 9 Kesavan M, Collins GP. Novel targets and therapies in T cell lymphoma. EMJ Oncol 2018; 6: 79-90
• 10 Kim YN, Bagot M, Pinter-Brown L. et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomized, controlled phase 3 trial. The Lancet Oncology 2018; 19: 1192-1204